Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a new patient cohort unlock the secrets of TB treatment success?

NCT ID NCT04236349

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This pilot study aims to test the feasibility of creating a large-scale cohort of tuberculosis (TB) patients in northern Paris, an area with high TB rates. Researchers will collect blood samples and clinical data from 30 participants over the course of their treatment to understand patient characteristics and treatment outcomes. The goal is to identify factors that may lead to adverse outcomes and ultimately improve TB control in the region.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
blood sample collection for immunogenetic analysis
What this could lead to
If successful, this pilot could pave the way for a large-scale TB cohort in France, helping identify factors linked to poor treatment outcomes and informing better TB control strategies.
What could go wrong
This is a small pilot study focused on feasibility, not treatment efficacy. It may not capture all relevant patient characteristics, and findings may not generalize beyond the specific population in northern Paris.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

May 2018

Finished

Feb 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patient with pulmonary or extrapulmonary tuberculosis

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient newly admitted to a consultation or hospitalization at a participating facility * Patient with pulmonary or extrapulmonary tuberculosis confirmed on a suggestive bacteriology (direct examination, GeneXpert MTB / RIF PCR and / or culture positive) or evocative histology (evocative aspect with gigantocellular epithelioid granuloma with or without caseous necrosis) or suspicion of tuberculosis not confirmed with introduction of anti-tuberculosis treatment Exclusion criteria : * Refusal to give one's non-opposition to participate in the study * Patient on antituberculous treatment for more than 21 days at the inclusion visit * Patient already participating in another research protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Extra pulmonary tuberculosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

extrapulmonary tuberculosis pulmonary tuberculosis tuberculosis Tuberculosis, Extrapulmonary

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extra pulmonary tuberculosis Pulmonary tuberculosis

Contacts and locations

Locations

  • Avicenne

    Bobigny, Seine Saint Denis, 93000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.